Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China
Helicobacter · 2023
DOI: 10.1111/hel.12970 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2023. Verfasst von Jie Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: The National Science Foundation of China, The Training Program of Clinical Medical Technology Innovation Ability of the Army Medical Center.
Abstract (Originalsprache)
Background
Potassium‐competitive acid blockers (P‐CAB) are recommended for the treatment of Helicobacter pylori infections, but dual therapy of P‐CAB with amoxicillin has been poorly studied. The current study compared the efficacy, adverse reactions, compliance, and effects on gut microbiota of 14‐day vonoprazan‐amoxicillin (VA) dual therapy with esomeprazole, bismuth potassium citrate, amoxicillin, and metronidazole (EBAM) quadruple therapy in treatment‐naive patients with H . pylori . Materials and Methods This was a multicenter, open‐label, randomized, and controlled, non‐inferiority study. Patients ( n = 194) enrolled from six centers were randomly divided into either the VA or EBAM group. H . pylori eradication was determined using 13 C urea breath tests (UBT) 4–6 weeks post‐treatment. Fecal samples were collected, and gut microbial populations were analyzed by 16S rDNA and metagenomic sequencing technology.
Results
Eradication rates of H . pylori in the VA and EBAM groups were 88.7% and 91.8%, respectively, according to intention‐to‐treat (ITT) analysis; 95.6% and 96.7% with per‐protocol (PP) analysis; and 94.5% and 96.7% with modified ITT (mITT) analysis (all p > 0.05). The incidence of adverse reactions in the VA group was significantly lower compared to the EBAM group, and compliance within both groups was good. There was no difference in α‐diversity or microbial composition in the VA and EBAM groups at one‐month post‐treatment compared to baseline, except for a markedly reduced abundance of Bacteroides in the EBAM group.
Conclusion
VA therapy achieved excellent eradication rates with low adverse reactions, good compliance, and little impact on gut microbiota. VA therapy should be recommended as a first‐line treatment against H . pylori .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing, China.
- Department of Gastroenterology, The 13th People's Hospital of Chongqing, Chongqing, China.
- Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, China.
- Department of Gastroenterology, The Second People's Hospital of Chongqing, Chongqing, China.
- Department of Gastroenterology, Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing, China.
- Department of Gastroenterology, Wenzhou Central Hospital, Wenzhou, China.
ORCID-Profile: De-Kui Zhang, Chun-Hui Lan
Förderung
- The National Science Foundation of China
- The Training Program of Clinical Medical Technology Innovation Ability of the Army Medical Center
Zitieren
APA
Hu, J., Mei, H., Su, N. Y., Sun, W. J., Zhang, D. K., Fan, L. L., He, P., Pan, J., Wang, X. W., Zou, P. Y., Liu, Y. X., Guo, Y., & Lan, C. H. (2023). Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China. Helicobacter. https://doi.org/10.1111/hel.12970
Vancouver
Hu J, Mei H, Su NY, Sun WJ, Zhang DK, Fan LL, et al. Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China. Helicobacter. 2023. doi:10.1111/hel.12970
BibTeX
@article{Hu2023,
author = {Hu, Jie and Mei, Hao and Su, Na-Yun and Sun, Wen-Jing and Zhang, De-Kui and Fan, Li-Lin and He, Ping and Pan, Jie and Wang, Xing-Wei and Zou, Pei-Ying and Liu, Yu-Xiang and Guo, Yan and Lan, Chun-Hui},
title = {Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China},
journal = {Helicobacter},
year = {2023},
doi = {10.1111/hel.12970}
}
EUVIMED